公开(公告)号：EP1050301A4

公开(公告)日：2004-11-17

申请号：EP99900351

申请日：1999-01-19

申请人： MITSUBISHI PHARMA CORP

发明人： SAKAI ATSUSHI ,  MASUDA RUMIKO ,  FUJII TSUNEO ,  MISHINA TADASHI ,  CHIBA KENJI

IPC分类号： A61K9/00 ,  A61K9/08 ,  A61K31/047 ,  A61K31/135 ,  A61K31/137 ,  A61K47/26 ,  A61K47/40 ,  A61P27/02 ,  A61P27/14 ,  A61P37/00 ,  A61P37/06 ,  A61P37/08

CPC分类号： B82Y5/00 ,  A61K9/0019 ,  A61K9/0048 ,  A61K9/08 ,  A61K31/137 ,  A61K47/26 ,  A61K47/40

摘要： Medicinal compositions being usable as solutions comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol or pharmaceutically acceptable acid-addition salts thereof and cyclodextrins as stabilizers optionally together with saccharides and being useful in inhibiting rejection reactions against bone marrow transplantation, immunotherapy for maintaining the same, or treating autoimmune diseases.

摘要翻译： 药物组合物可用作包含2-氨基-2- [2-（4-辛基苯基）乙基]丙烷-1,3-二醇或其药学上可接受的酸加成盐和环糊精作为稳定剂的溶液，任选与糖类一起使用并可用于 抑制针对骨髓移植的排斥反应，维持其的免疫疗法或治疗自身免疫疾病。

公开(公告)号：EP1284287A4

公开(公告)日：2004-10-13

申请号：EP01930008

申请日：2001-05-09

申请人： MITSUBISHI PHARMA CORP

发明人： TAKASHIMA SHIGEMITSU ,  HEIKE YUJI

IPC分类号： C12N15/86 ,  C12N7/00 ,  C12N15/09

CPC分类号： C12N15/86 ,  C12N2710/10043

摘要： Means of inhibiting aggregation which occurs after purifying a virus vector. Namely, 1) a method of preparing a virus vector which at least involves (1) the step of purifying a virus vector, and (2) the step of sterilizing the purified vector obtained in the above (1) by filtering in the presence of serum albumin; 2) medicinal compositions containing a virus vector and serum albumin; 3) a method of inhibiting the aggregation of a virus vector or a method of stabilizing a virus vector characterized by adding serum albumin to a solution containing the virus vector; and 4) medicinal compositions containing a virus vector having been sterilized by filtration which are substantially free from the aggregation of the virus vector and/or substantially free from any decrease in the virus activity after storing at room temperature at least for 7 days in the state of a solution.

公开(公告)号：EP1256581A4

公开(公告)日：2004-10-06

申请号：EP01902793

申请日：2001-02-07

申请人： MITSUBISHI PHARMA CORP

发明人： YAMAZAKI SATOSHI

IPC分类号： A61K31/439 ,  A61P1/04 ,  C07D495/04 ,  C07D519/00 ,  C07D453/02 ,  A61K31/55

CPC分类号： C07D495/04 ,  A61K31/439 ,  A61K31/4743

摘要： Compounds represented by the following general formula, pharmaceutically acceptable salts thereof, or hydrates of both exhibit both an excellent enterokinesis-promoting activity and an inhibitory activity against acid secretion and are excellent in safety, thus being useful as preventive or therapeutic agents for gastric or esophageal regurgitation. Formula (1), wherein R?1 and R2¿ are each independently hydrogen or lower alkyl; and A is a substituent selected from the group consisting of 1-azabicyclo[3.2.2]nonyl, 1-azabicyclo[2.2.2]octyl and N-oxides of both.

公开(公告)号：EP1298217A4

公开(公告)日：2004-09-08

申请号：EP01949913

申请日：2001-07-04

申请人： MITSUBISHI PHARMA CORP

发明人： SUGA KENICHI ,  OMASA TAKESHI ,  KISHIMOTO MICHIMASA ,  KATAKURA YOSHIO ,  OHDA TOYOO ,  MIKI HIDEO ,  KOBAYASHI KAORU

IPC分类号： C12P21/00

CPC分类号： C12P21/005

摘要： A means of controlling sugar chain-modification and sugar chain structure in the production of a glycoprotein with the use of gene recombination techniques. A process for producing a glycoprotein by culturing a gene recombinant host in a medium characterized in that the relative sugar consumption speed is employed as an indication and changed to thereby modify the sugar chain structure attached to the protein.

公开(公告)号：EP1374888A4

公开(公告)日：2004-07-07

申请号：EP02701642

申请日：2002-02-28

申请人： MITSUBISHI PHARMA CORP

发明人： IMAIZUMI REI

IPC分类号： A61K38/00 ,  A61P19/02 ,  A61P29/00 ,  A61P43/00 ,  C07K14/50 ,  C07K14/51 ,  A61K31/711 ,  A61K38/17 ,  A61K38/57 ,  A61K48/00

CPC分类号： C07K14/51 ,  A61K38/00 ,  C07K14/503

摘要： It is intended to provide remedies efficacious for arthritis deformans and rheumatoid arthritis. Namely, remedies for arthritis deformans and rheumatoid arthritis which contain, as the active ingredient, chondromodulin-I protein having an activity of proliferating articular cartilage cells either alone or in the coexistence with a basic fibroblast growth factor and an activity of inhibiting accelerated degradation of cartilage matrix.

公开(公告)号：EP1163910A4

公开(公告)日：2003-11-12

申请号：EP00909782

申请日：2000-03-21

申请人： MITSUBISHI PHARMA CORP

发明人： IIZUKA KUNIHIKO ,  DOBASHI KUNIO ,  UEHATA MASAYOSHI

IPC分类号： A61K31/00 ,  A61K31/34 ,  A61K31/44 ,  A61K31/4409 ,  A61K31/443 ,  A61K31/445 ,  A61K31/4525 ,  A61K31/50 ,  A61K31/501 ,  A61P11/00 ,  A61K45/00

CPC分类号： A61K31/501 ,  A61K31/00 ,  A61K31/34 ,  A61K31/44 ,  A61K31/4409 ,  A61K31/443 ,  A61K31/445 ,  A61K31/4525 ,  A61K31/50

摘要： An agent for the prophylaxis and treatment of interstitial pneumonia and pulmonary fibrosis, which contains a compound having a Rho kinase inhibitory activity, particularly an agent for the prophylaxis and treatment of interstitial pneumonia and pulmonary fibrosis, which contains a compound of the formula (I) wherein each symbol is as defined in the specification, as the compound having a Rho kinase inhibitory activity, is provided.

公开(公告)号：EP1300141A4

公开(公告)日：2003-07-16

申请号：EP01934539

申请日：2001-06-05

申请人： LEQUIO PHARMA CO LTD ,  MITSUBISHI PHARMA CORP

发明人： OKU KINUKO ,  IWAMOTO TAKAKO ,  ONO TAKASHI

IPC分类号： A61K9/00 ,  A61K31/167 ,  A61K31/245 ,  A61K33/06 ,  A61P1/00 ,  A61P23/02 ,  A61P43/00 ,  A61K9/08

CPC分类号： A61K33/06 ,  A61K9/0031 ,  A61K31/167 ,  A61K31/245 ,  A61K31/70 ,  A61K31/165 ,  A61K2300/00

摘要： A medical composition kit for treating rectal submucous lesioned abnormal tissue wherein respective containers are unsealed upon being used and respective contents are mixed to obtain a preparation for injection, characterized in that respective single doses of a therapeutic preparation and an agent for local anesthesia are separately packed in containers, the therapeutic preparation contains 1 to 10 % of a water-soluble aluminum compound and 0.01 to 2 % of tannic acid and the agent for local anesthesia contains 0.1 to 1 % of lidocaine hydrochloride or 0.5 to 5 % of procaine hydrochloride. The kit has an optimum compounding ratio between a therapeutic preparation and an agent for local anesthesia.

摘要翻译： 1.一种用于治疗直肠粘膜下粘膜损伤的异常组织的药物组合物，其中各个容器在使用时开封并且各自的内容物被混合以获得用于注射的制剂，其特征在于分别包装单独剂量的治疗制剂和局部麻醉剂 在容器中，治疗制剂含有1至10％的水溶性铝化合物和0.01至2％的单宁酸，局部麻醉剂包含0.1至1％的盐酸利多卡因或0.5至5％的盐酸普鲁卡因。 该试剂盒在治疗制剂和局部麻醉剂之间具有最佳配比。

公开(公告)号：EP1081132A4

公开(公告)日：2002-11-13

申请号：EP99921188

申请日：1999-05-19

申请人： MITSUBISHI PHARMA CORP

发明人： GOTOU TOMOKAZU ,  TAKEDA SHINJI ,  MAEDA KAZUHIRO ,  YOSHIDA TOMOHIRO ,  SUGIYAMA NAOKI ,  TAKEMOTO TADAHIRO

IPC分类号： A61P19/02 ,  C07C259/06 ,  C07D209/46 ,  C07D209/48 ,  C07D233/72 ,  C07D307/52 ,  C07D309/12 ,  C07D405/12 ,  C07D405/14 ,  C07C233/31

CPC分类号： C07D209/48 ,  C07C259/06 ,  C07D209/46 ,  C07D233/72 ,  C07D307/52 ,  C07D309/12 ,  C07D405/12 ,  C07D405/14

摘要： Hydroxamic acid derivatives represented by general formula (I) or pharmacologically acceptable salts thereof; medicinal compositions containing the same and medicinal utilization thereof wherein each symbol has the meaning as defined in the specification. Because of having TNF-α production inhibitory effect, these derivatives or pharmacologically acceptable salts thereof are useful in preventing/treating autoimmune diseases and inflammatory diseases, for example, sepsis, MOF, rheumatoid arthritis, Crohn's disease, cachexia, myasthenia gravis, systemic lupus erythematosus, asthma, I type diabetes and psoriasis.

公开(公告)号：EP0940400A4

公开(公告)日：2002-10-02

申请号：EP97909602

申请日：1997-10-22

申请人： MITSUBISHI PHARMA CORP

发明人： AKAHOSHI FUMIHIKO ,  ASHIMORI ATSUYUKI ,  YOSHIMURA TAKUYA ,  EDA MASAHIRO ,  SAKASHITA HIROSHI ,  NAKAJIMA MASAHIDE ,  IMADA TERUAKI

IPC分类号： C07D413/12 ,  A61K31/435 ,  A61K38/00 ,  C07K5/078 ,  A61K31/505 ,  C07D239/47 ,  C07D417/12 ,  C07D498/04 ,  C07K5/04

CPC分类号： C07K5/06139 ,  A61K38/00

摘要： Heterocyclic amide compounds represented by general formula (I) or pharmacologically acceptable salts thereof; medicinal compositions thereof; and medicinal uses of the same wherein each symbol is as defined in the specification. These compounds and pharmacologically acceptable salts thereof have excellent effects of inhibiting chymases on mammals including human being and can be administered orally or parenterally. Thus, they are useful as chymase inhibitors in preventing and treating various diseases caused by chymases typified by those caused by angiotensin II.

公开(公告)号：EP1157694A4

公开(公告)日：2002-08-28

申请号：EP99973258

申请日：1999-11-30

申请人： NISSAN CHEMICAL IND LTD ,  MITSUBISHI PHARMA CORP

发明人： TANIKAWA KEIZO ,  TSURUZOE NOBUTOMO ,  SHUDO NORIMASA ,  YAMASHITA TORU ,  ISHIWATA NORIHISA ,  KIDO HIDEAKI ,  EBISU HAJIME ,  HAYASHI KAZUTAKA ,  KUBO YOSHIJI ,  NAKAMURA NORIFUMI

IPC分类号： A61K31/50 ,  A61K31/501 ,  A61P15/10

CPC分类号： A61K31/501 ,  A61K31/50

摘要： An erectile dysfunction remedy which comprises as the active ingredient a 3(2H)-pyridazinone derivative represented by formula (I) or a pharmacologically acceptable salt thereof, wherein the symbols each is the same as defined in the description.